Merck quietly ditches its sac-tmt copy
MK-6837 has been discontinued, the company discloses.
Another fianlimab fiasco for Regeneron
The company discontinues the Lag3 project in lung cancer.
Erasca dips on patient death
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
Crossover hits Compass
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
ASCO 2026 preview – recent wins come under the spotlight
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
AACR 2026 – Matisse paints a mixed picture for Innate
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
